Skip to main content

Table 7 Hazard ratio for all-cause mortality associated with the presence of lung cancer in patients with intact AAA

From: Outcomes after aortic aneurysm repair in patients with history of cancer: a nationwide dataset analysis

All-cause mortality

Crude HR (95% CIs)

Adjusted HR (95% CIs)*

Model 1

Model 2

Patients with intact AAA treated by EVAR or OSR (n = 11,785)

 30-day mortality

2.93

(1.37–6.28)

2.98

(1.39–6.41)

2.97

(1.38–6.39)

 90-day mortality

2.33

(1.37–3.99)

2.24

(1.31–3.84)

2.27

(1.33–3.89)

 Total mortality

2.07

(1.62–2.65)

1.90

(1.49–2.43)

1.95

(1.52–2.49)

Patients with intact AAA treated by EVAR (n = 7903)

 30-day mortality

2.85

(1.15–7.03)

3.05

(1.23–7.58)

3.04

(1.22–7.58)

 90-day mortality

1.84

(0.94–3.58)

1.84

(0.94–3.58)

1.90

(0.97–3.71)

 Total mortality

1.91

(1.44–2.54)

1.77

(1.33–2.36)

1.81

(1.36–2.41)

Patients with intact AAA treated by OSR (n = 3882)

 30-day mortality

3.26

(0.79–13.47)

3.08

(0.74–12.79)

3.26

(0.78–13.67)

 90-day mortality

4.09

(1.66–10.07)

3.57

(1.44–8.83)

3.69

(1.48–9.19)

 Total mortality

2.33

(1.44–3.77)

2.25

(1.39–3.64)

2.29

(1.41–3.71)

  1. AAA Abdominal aortic aneurysm
  2. *Model 1: Adjusted for age and sex
  3. Model 2: Further adjusted for insurance type (National Health Insurance or Medical Aid Program), hospital type (tertiary hospital or general/small hospital), regional area (urban or rural), CCI (0–1, 2, or ≥ 3), and comorbidities (hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, or end-stage renal disease)